Nirmatrelvir-Ritonavir Results in Modest Reductions in COVID-19 Hospitalization and Death in Patients on Immunosuppressants
Nirmatrelvir-Ritonavir Results in Modest Reductions in COVID-19 Hospitalization and Death in Patients on Immunosuppressants
Heavily Vaccinated Contract Omicron, Blanketed with Monoclonal Antibodies, Leaving Little Benefit of Paxlovid
By Peter A. McCullough, MD, MPH
Severe COVID-19 respiratory illness is partly characterized by cytokine storm or a hyper-immune response. A principle of treatment is to used corticosteroids, which are classic immunosuppressant drugs. Hence, the “immunocompromised” are not mechanistically at high risk for COVID-19 outcomes. The main issue of clinical concern is frailty, since those on immunosuppressants with auto-immune disease, organ transplantation, or malignancy are medically frail and hence, worrisome for the risk of hospitalization or death with COVID-19.
Dormuth et al reported on multiple cohorts of patients with varying degrees of medical conditions who contracted Omicron sadly after taking multiple shots of COVID-19 vaccines. As you can see, 100% were treated with monoclonal antibodies which have been consistently safe and effective. While not reported, likely other drugs in the McCullough Protocol were utilized.
None of the cohorts had a significant benefit from Paxlovid except for CEV2 of whom 98% were on immunosuppressives. Here the outcome was reduced by 49% however, the authors do not separately report mortality. This is usually a signal there was no difference in death.
This paper adds to our knowledge base in the following manner: 1) in multiple cohorts, heavy COVID-19 vaccination failed to stop Omicron infections, 2) blanket use of monoclonal antibodies appeared to lower the risk of hospitalization and death in all groups, 3) there is little benefit to Paxlovid on top of monoclonal antibodies (and probably other therapies) except in those on immunosuppressants at baseline.
Please subscribe to Courageous Discourse as a paying or founder member so we can continue to bring you the truth.
Peter A. McCullough, MD, MPH
President, McCullough Foundation
Will you be revising your protocol, Dr. McCullough to reserve Paxlovid for those with baseline immunosuppression or wait for further confirmatory studies? Will you also inform your patients that Paxlovid and molnupiravir were developed using cell cultures derived from the harvested kidney of an aborted healthy baby? I’m still a big fan and admirer of yours but this last question is of great importance to me.
Thank you for writing so clearly and for interpreting where readers are likely to need it.